Krka has announced the launch of Robexera, the first generic robenacoxib solution for the treatment of pain and inflammation associated with chronic osteoarthritis (OA) and soft tissue surgery in dogs.¹ 

Robexera is a COX2 NSAID formulation which delivers anti-inflammatory pain relief with a once-a-day dosing regime^2,3,4.  

The product is presented as a flavoured chewable tablet for easier administration by pet owners.

For simplicity when dispensing, it comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.

Charlotte Read, Krka’s UK Key Account Manager, said: “Delivering reliable, cost-effective perioperative pain relief for soft tissue surgery is an everyday concern for veterinary practices, while OA is the most common cause of chronic pain in dogs⁵. 

"This is why we’re particularly pleased to announce the first generic robenacoxib, Robexera. 

“Bioequivalent to the originator product⁶, Robexera provides fast-acting and targeted pain relief, giving enhanced value to veterinary practices and enabling them to offer their clients improved affordability, particularly for those whose animals are on long term pain-management programmes or have other health issues.”

Viktor Kozjan, General Manager Krka UK, added: “The launch of Robexera is further confirmation of Krka’s commitment to develop solutions that are tried and trusted but also flexible and affordable for our customers and their clients.”

Robexera is now available to order from all national UK veterinary wholesalers. 

References

1. Product Information Database (defra.gov.uk)
2. Silber HE, et al.(2010) Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis. Pharm Res 27:2633-2645. doi: 10.1007/s11095-010-0262z . 
3. Kongara K. , Chambers J.C. (2018) “Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy and place in therapy.” Veterinary medicine (Auckland, N.Z.) vol. 9 53-61. 15 Aug.2018, doi:10.2147/VMRR.S170893
4. Lees, P., et al. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 45, 325–351. https://doi.org/10.1111/jvp.13052
5. https://caninearthritis.co.uk/what-is-arthritis/arthritis-the-basics/
6. BEQ : Regulatory approved Biowaiver demonstrating bioequivalence to the reference (Registration procedure parallel to DCP procedure No. IE/V/0775/001-004/DC, GB Vm number: 01656/5031 (20 mg); PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; https://www.hpra.ie/img/uploaded/swedocuments/Public_AR_VPA10774-075- 003_21082023130723.pdf

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.